Treatment With MK6592 and an Anti-Cancer Drug in Patients With Advanced Solid Tumors
This study has been terminated.
Information provided by:
First received: August 1, 2006
Last updated: February 12, 2008
Last verified: February 2008
A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors|
Resource links provided by NLM:
Further study details as provided by Merck:
Primary Outcome Measures:
- Safety and tolerability of MK6592 alone and in combination with docetaxel [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Observance of objective tumor responses in patients treated with MK6592 combined with docetaxel [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
|Study Start Date:||March 2007|
|Study Completion Date:||July 2007|
Arm 1: study drug
MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
Arm 2: study drug + comparator
MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.Drug: comparator: docetaxel
docetaxel, delivered as a standard IV infusion.
Contacts and Locations